Contributions of 12/15-Lipoxygenase to Bleeding in the Brain Following Ischemic Stroke.

12-HETE 15-HETE Blood-brain barrier Eicosanoid Hemorrhage Hemorrhagic transformation Ischemia Ischemic stroke Lipoxygenase Neuroprotection STAT6 Tissue plasminogen activator Warfarin tPA

Journal

Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103

Informations de publication

Date de publication:
2019
Historique:
entrez: 29 9 2019
pubmed: 29 9 2019
medline: 3 10 2019
Statut: ppublish

Résumé

Ischemic strokes are caused by one or more blood clots that typically obstruct one of the major arteries in the brain, but frequently also result in leakage of the blood-brain barrier and subsequent hemorrhage. While it has long been known that the enzyme 12/15-lipoxygenase (12/15-LOX) is up-regulated following ischemic strokes and contributes to neuronal cell death, recent research has shown an additional major role for 12/15-LOX in causing this hemorrhagic transformation. These findings have important implications for the use of 12/15-LOX inhibitors in the treatment of stroke.

Identifiants

pubmed: 31562627
doi: 10.1007/978-3-030-21735-8_12
pmc: PMC7278041
mid: NIHMS1582813
doi:

Substances chimiques

Arachidonate 15-Lipoxygenase EC 1.13.11.33

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-131

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS049430
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS087165
Pays : United States
Organisme : NINDS NIH HHS
ID : UG3 NS106854
Pays : United States
Organisme : NINDS NIH HHS
ID : UH3 NS106854
Pays : United States

Références

Blood. 2007 Nov 1;110(9):3407-16
pubmed: 17666570
Stroke. 2006 Dec;37(12):3014-8
pubmed: 17053180
Biochim Biophys Acta. 1970 Oct 6;218(1):1-10
pubmed: 5473492
Sci Rep. 2015 Jan 20;5:7890
pubmed: 25601765
Stroke. 2008 Sep;39(9):2538-43
pubmed: 18635843
Brain Res. 2018 Jan 1;1678:123-128
pubmed: 29079502
Stroke. 2017 Feb;48(2):445-451
pubmed: 28057806
Stroke. 2005 Oct;36(10):2258-64
pubmed: 16166580
Nature. 1998 Sep 24;395(6700):392-5
pubmed: 9759730
J Neurosci. 2002 Jun 15;22(12):4932-41
pubmed: 12077190
FASEB J. 2013 Feb;27(2):437-45
pubmed: 23070608
Biochim Biophys Acta. 2015 Apr;1851(4):308-30
pubmed: 25316652
J Biol Chem. 1996 Sep 27;271(39):24055-62
pubmed: 8798642
FASEB J. 2017 Feb;31(2):491-504
pubmed: 27825104
FEBS Lett. 2001 Jan 26;489(1):51-4
pubmed: 11231012
Cold Spring Harb Perspect Biol. 2011 Jun 01;3(6):
pubmed: 21123392
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
Sci STKE. 2002 Feb 12;2002(119):re1
pubmed: 11842242
FEBS Lett. 1975 Dec 1;60(1):149-52
pubmed: 6318
Curr Opin Hematol. 2002 Mar;9(2):93-100
pubmed: 11844990
Science. 1984 May 25;224(4651):886-9
pubmed: 6719118
Cell Calcium. 2018 Mar;70:47-55
pubmed: 28545724
Stroke. 2011 Apr;42(4):1116-21
pubmed: 21330626
Ann Neurol. 2013 Jan;73(1):129-35
pubmed: 23192915
Bioorg Med Chem. 2016 Mar 15;24(6):1183-90
pubmed: 26899595
Exp Neurol. 2019 Mar;313:98-108
pubmed: 30521790
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
J Cereb Blood Flow Metab. 2015 Dec;35(12):2043-51
pubmed: 26174325
Int J Cancer. 2013 Oct 15;133(8):1784-91
pubmed: 23526143
Nature. 1987 Jul 2-8;328(6125):38-43
pubmed: 2439918
J Neurosci Res. 2008 Mar;86(4):904-9
pubmed: 17960827
Brain Res. 2004 Apr 9;1004(1-2):198-202
pubmed: 15033436
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
J Biol Chem. 2010 Mar 26;285(13):9908-18
pubmed: 20133938
Stroke. 2019 Feb;50(2):520-523
pubmed: 30602353
J Med Chem. 2014 May 22;57(10):4035-48
pubmed: 24684213
Neuron. 1997 Aug;19(2):453-63
pubmed: 9292733

Auteurs

Yi Zheng (Y)

Neuroprotection Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.

Yu Liu (Y)

Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital of Jinan University, Zhuhai, Guangdong, China.

Hulya Karatas (H)

Institute of Neurological Sciences and Psychiatry, Hacettepe University, Ankara, Turkey.

Kazim Yigitkanli (K)

Medicana Bursa Hospital, Neurosurgery Clinic, Bursa, Turkey.

Theodore R Holman (TR)

Department of Chemistry and Biochemistry, University of California at Santa Cruz, Santa Cruz, CA, USA.

Klaus van Leyen (K)

Neuroprotection Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. klaus_vanleyen@hms.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH